" "
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Lonza and Agennix Sign Development and Manufacturing Deal for Production of Talactoferrin

Published: Thursday, April 19, 2012
Last Updated: Thursday, April 19, 2012
Bookmark and Share
Lonza will manufacture talactoferrin at its microbial facility in Kourim, Czech Republic.

Lonza and Agennix AG have announced an agreement for the production of Agennix’s first-in-class oral Dendritic Cell Mediated Immunotherapy (DCMI), talactoferrin, currently in Phase III testing for the treatment of non-small cell lung cancer (NSCLC).

Under the agreement, Lonza will produce commercial material at its microbial manufacturing facility in Kouřim, Czech Republic.

This agreement initiates the process needed to be able to ultimately seek approval for Lonza as a second manufacturer of talactoferrin after the initial commercial launch.

“We are committed to supporting emerging therapeutics through clinical trial milestones,” said Dr. Stephan Kutzer, COO Lonza Custom Manufacturing.

Dr. Kutzer continued, “Our partnership with Agennix is an example of this commitment and demonstrates Lonza’s ability to offer access to our development and manufacturing expertise at an early stage of production.”

Rajesh Malik, M.D., Chief Medical Officer and Management Board member of Agennix, said: “We are pleased to enter this agreement with Lonza, which has extensive experience manufacturing biologics on a commercial scale. In anticipation of positive Phase III data and a potential product approval, it is important that we have more than one manufacturer in place to ensure we can meet anticipated commercial demand and that we have security of supply.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Leading Industry Experts to Present at Lonza’s 2nd Global Endotoxin Testing Summit
A growing list of industry experts have signed up to join the speaker panel at Lonza’s 2nd Global Endotoxin Testing Summit from 23-25 May 2016, Annapolis, MD, and Pickering Beach, DE (USA).
Tuesday, March 01, 2016
Lonza to Build Capabilities for Drug Product Development
Company to Develop Drug Product Services for Customers by building its capabilities step-wise over the coming years.
Friday, February 05, 2016
Lonza to Build Capabilities for Drug Product Development Services
Lonza is entering the field of Drug Product Development Services for customers by building its capabilities step-wise over the coming years.
Friday, February 05, 2016
Lonza and Benitec Enter Agreement
Agreement to develop scalable AAV manufacturing process for ddRNAi therapeutics.
Friday, October 09, 2015
Lonza and CytoMate Collaboration on CytoSMART™ Technology
Agreement for global distribution of the new technology which is designed for easy, affordable live cell imaging.
Thursday, March 05, 2015
Lonza and arGEN-X Announces Commercial License Agreement
A multi-product GS Xceed™ license agreement for the production of therapeutic antibodies.
Friday, February 20, 2015
Lonza and BioWa Sign Licensing Agreement with MedImmune
MedImmune has licensed Potelligent® CHOK1SV Cell Line Technology to both Companies.
Monday, December 16, 2013
Lonza and Hyglos Reach Agreement for Endotoxin Detection Patents
Agreement allows Hyglos to use recombinant factor C technology to produce its own endotoxin products.
Friday, March 15, 2013
Lonza to Expand ADC Manufacturing Capacity
Capacity expansion is expected to be complete in the second quarter of 2014.
Thursday, January 10, 2013
Lonza Appoints Richard Ridinger as New CEO
Board of Directors elects Mr. Ridinger at a meeting on 2 April 2012.
Thursday, April 05, 2012
Lonza Expands Singapore Bioservices
The expansion will support cell line construction, upstream and downstream process development, and a broad range of analytical services.
Monday, June 13, 2011
Lonza Selects IDBS to Optimize Bioprocess Execution & Knowledge Management
Lonza has chosen IDBS to provide an electronic data management and execution solution for mammalian cell culture process development. Lonza will deploy IDBS's Bioprocess Execution System to optimize the management of process development data and drive operational excellence.
Wednesday, January 05, 2011
Lonza Acquires Viral Vaccine and Vector Manufacturer Vivante GMP Solutions
Lonza expands its custom service platform to viral vaccines and gene therapy vectors.
Tuesday, August 31, 2010
Elusys Therapeutics and Lonza Enter Into Manufacturing Agreement
Lonza provides process development services and manufacturing capacity for this product using Lonza's GS Gene Expression System™.
Wednesday, June 17, 2009
Lonza Initiates Large Scale Production Capacity and Technology Platform for Antibody Drug Conjugates
Lonza plans to start large scale production of emerging product class Antibody Drug Conjugates to be utilized primarily in the treatment of cancer.
Friday, May 18, 2007
Scientific News
Improving Natural Killer Cancer Therapy
Vanderbilt University researchers discover transcription factor critical for NK cell expansion. Findings could lead to increased therapeutic efficacy.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
Autism and Cancer Share a Remarkable Number of Risk Genes
Researchers with the UC Davis Comprehensive Cancer Center, MIND Institute identify more than 40 common genes.
Number Of Known Genetic Risk Factors For Endometrial Cancer Doubled
An international collaboration of researchers has identified five new gene regions that increase a woman’s risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine.
Genetic Variant May Help Explain Why Labradors Are Prone To Obesity
A genetic variation associated with obesity and appetite in Labrador retrievers – the UK and US’s favourite dog breed – has been identified by scientists at the University of Cambridge. The finding may explain why Labrador retrievers are more likely to become obese than dogs of other breeds.
FNIH Launches Project to Evaluate Biomarkers in Cancer Patients
Company has announced that it has launched a new project to evaluate the effectiveness of liquid biopsies as biomarkers in colorectal cancer patients.
Flowering Regulation Mechanism Discovered
Monash researchers have discovered a new mechanism that enables plants to regulate their flowering in response to raised temperatures.
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!